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• Role of 1 in vivo is to allow microglia to leave neuronal injuries.
• 1 Agonists block microglial responses to neuronal injuries.
• 1 Agonists do not affect microglial motility and their ability to collect dying neurons.
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a b s t r a c t
Microglial cells are responsible for clearing and maintaining the central nervous system (CNS) microen-
vironment. Upon brain damage, they move toward injuries to clear the area by engulﬁng dying neurons.
However, in the context of many neurological disorders chronic microglial responses are responsible
for neurodegeneration. Therefore, it is important to understand how these cells can be “switched-off”
and regain their ramiﬁed state. Current research suggests that microglial inﬂammatory responses can be
inhibited by sigma () receptor activation. Here, we take advantage of the optical transparency of the
zebraﬁsh embryo to study the role of 1 receptor in microglia in an intact living brain. By combining
chemical approaches with real time imaging we found that treatment with PB190, a 1 agonist, blocks
microglial migration toward injuries leaving cellular baseline motility and the engulfment of apoptotic
neurons unaffected. Most importantly, by taking a reverse genetic approach, we discovered that the role
of 1 in vivo is to “switch-off” microglia after they responded to an injury allowing for these cells to
leave the site of damage. This indicates that pharmacological manipulation of 1 receptor modulates
microglial responses providing new approaches to reduce the devastating impact that microglia have in
neurodegenerative diseases.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In the CNS, immune responses depend on the recruitment
and activation of microglia, the resident CNS phagocytes. Under
physiological conditions, microglia display low cell body dis-
placement and scan the surrounding environment with their ﬁne
branches [15]. In the presence of brain injuries, both in mouse
and ﬁsh, microglia move toward damage by following ATP signal-
ing via P2Y12 receptors [5,20]. Here, microglia release different
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factors such as cytokines (IL-1, TNF-, IL-6), chemokines (MCP-
1), excitatory neurotransmitters (glutamate), complement factors,
prostaglandins and reactive oxygen species [10]. To date, while it
is clear that microglial responses are important for clearing the
damaged area; it is also evident that these cells have to leave
injuries to allow subsequent tissue repair [11,14]. Unfortunately,
our knowledge on how they move away from damage is limited
due to an inability to study these events in vivo. In addition, in the
context of many neurological disorders, chronic microglial acti-
vation is known to be detrimental as it leads to widespread cell
death and neurodegeneration [6,23]. For example, involvement of
microglia in the Alzheimer’s disease has also been shown upon
accumulation of amyloid- (A) and this determines a cascade
of events in glia cells leading to neuronal death [8,16]. Therefore,
http://dx.doi.org/10.1016/j.neulet.2015.02.004
0304-3940/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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molecular factors involved in the modulation of microglial
responses to CNS stimuli (e.g., ischemia, stroke, A, etc.) are of
great interest, and sigma () receptors are among them. Two sub-
types of  receptors, namely 1 and 2, have been identiﬁed in the
early 1990s [18], and although their mechanisms of action are not
fully understood, these receptors are important targets for phar-
maceutical research. While the 2 subtype is investigated in cancer
related research [13,1], neuroprotective and neuroregulative func-
tions havebeenproposed for 1 receptors,with 1 ligands reported
to protect against brain ischemia and to potentiate neurite out-
growth [24]. Lately, 1 receptors have been found in microglia,
and recent studies with primary cultures of microglia show that
 receptor agonists are able to decrease microglia activation
[7]. The  receptors non-selective agonists di-orto-tolyl-guanidine
(DTG), and 5-ethoxy-2-[2-(morpholino)ethylthio]benzimidazole
(afobazole) were shown to decrease microglia migration in
response to ATP by reducing ATP-evoked increases in Ca2+ [4].
While afobazole,was shown to reduce neuronal and glial cell injury
in vitro following ischemia, very recently, another 1 receptor ago-
nist 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) has been shown
to reduce neonatal excitotoxic brain lesions by inhibiting microglia
activation [26]. Therefore, 1 receptors appear to be important
targets for modulating microglia responses to brain insults. To fur-
ther investigate the role of 1 receptors in modulating microglial
activity, we selected the well characterized 1 receptor ligand
PB190 (4-methyl-1-[4-(6-methoxy-1,2,3,4-tetrahydronaphthalen-
1-yl)butyl]piperidine) [3] and studied its effect by live imaging
of optically transparent zebraﬁsh embryos. Zebraﬁsh embryonic
brain has been previously shown to be a powerful system to study
microglia in vivo as zebraﬁsh microglia cells and their responses to
damage are very well conserved and comparable to their murine
counterpart [12,17,20].
Herein, by combining chemical treatments with live imaging in
ﬁshembryos,we showthat the administrationof1 agonists PB190
andDTG signiﬁcantly reducesmicroglialmigration toward injuries,
while base line motility and engulfment of neurons remain unaf-
fected. Taking advantage of reverse genetics in zebraﬁsh, we ﬁnd
that the role of 1 receptor in vivo is to resolve microglial activa-
tion allowing for these cells to leave the site of damage after that
they have responded to an injury. These results show that chemical
tools actingat the level of1 receptormodulatemicroglial activities
and can be used in the context of brain injuries to control speciﬁc
microglial functions.
2. Materials and methods
2.1. Transgenic ﬁsh lines and ﬁsh maintenance
Fish were kept at 26.5 ◦C in a 14h light/10h dark cycle. Embryos
were raised at 28.5 ◦C inE3-solution. To avoidpigmentation, 0.003%
PTUwas added at 1dpf.Microgliawere visualized using pu1::Gal4-
UAS::TagRFP [20] and Ca2+ using beta-actin::GCaMP3.1 [20]. For
live imaging, only 3.5dpf old zebraﬁsh embryos were used. They
were anesthetized in 0.01% tricane andembedded in 1.5% lowmelt-
ing agarose.
2.2. Confocal imaging and laser injuries
Imaging was done using an Olympus FV 1000 and an Andor
Spinning Disk Confocal with 20x/NA0.7 and 40x/NA1.15 objec-
tives. Embryos were anesthetized in 0.01% tricane and embedded
in 1.5% low melting agarose. In general, 30–40 z-stacks span-
ning 45–60m of the ﬁsh brain were captured and ﬂattened by
maximumprojection in Imaris (Bitplane) andFiji. Lesionsweregen-
erated using a 532nm laser coupled to the FV 1000 and a pulsed
355nm laser coupled to the Andor SpinningDisk using the protocol
described in [20]. In particular, ablations were done at anatomi-
cal points that can be identiﬁed easily. Ablations were conﬁrmed
under the microscope and they were previously shown to lead to
the death of approximately 200 neurons without either damaging
the blood–brain barrier or perturbing normal larval development
[20]. Images were analysed using both Imaris and Fiji. Statistical
analysis was performed using Prism6 (GraphPad). For all values a
nonparametric distribution was assumed.
2.3. Genetic and pharmacological perturbations
Morpholino oligonucleotides (Sigma1: 5′-GAACATTATTGT-
TTTACTCACCCGC-3′) were obtained from Gene Tools Inc., and
injected at a concentration of 0.9mM with 0.2% Phenolred (Sigma)
and 0.1M KCl (Sigma) into one-cell stage embryos. Knock-down
was checked using a 1 polyclonal antibody (Santa Cruz sc-22948).
Acridine orange staining was performed by incubating zebraﬁsh
larvae in 10g/mL acridine orange (Sigma) in E3 for 60min fol-
lowed by several washes in fresh E3 medium.
2.4. Reagents
All chemicals used in this study were of analytical grade. PB190
was synthesizedaccording to thepreviously reportedprocedure [3]
and used at a concentration of 100m. DTG was purchased from
Aldrich and used at a concentration of 100m. The chemicals have
been added to the E3 ﬁsh medium plus 1% DMSO.
2.5. Immunoblotting
Western blot analysis was performed in accordance to the
method described by Westerﬁeld [25]. Proteins extracts produced
from 3.5 dpf old embryos were separated in 10% polyacrylamide
gels and transferred to Hybond ECL membranes (Amersham Phar-
macia Biotech) by wet-blotting. For detection, we have followed
the standardmethodof ECLWesternblottingdetection (Amersham
Pharmacia Biotech). The polyclonal against 1 receptor (Santa Cruz,
SC-22948) was added at a concentration of 1/100.
3. Results
3.1. Microglial response to neuronal injuries can be speciﬁcally
blocked by the usage of 1 receptor agonists
In order to study microglial responses to neuronal cell death in
the living zebraﬁsh brain, we developed a UV pulsed cutting laser
attached toaSpinningDiskConfocalmicroscope to induceneuronal
cell death without damaging the blood–brain barrier nor perturb-
ing normal larval development [20]. Systemic ablation of neuronal
cells leads to microglial branching and migration toward the site of
injury (Fig. 1C1–C3; [20]. To further investigate the role of 1 recep-
tors in modulating microglial responses to injuries, we selected
PB190 (4-methyl-1-[4-(6-methoxy-1,2,3,4-tetrahydronaphthalen-
1-yl) butyl]piperidine; [3], a well characterized 1 receptor ligand
to study its effect on microglia by using live imaging. PB190 was
shown to behave as a 1 receptor agonist both in vitro and in vivo
[22]. Moreover, it displays better 1 pharmacological proﬁle com-
pared to DTG (Ki =26.2nM for 1 receptor and Ki =40nM for 2
receptor, respectively) [2] and afobazole (Ki =5.9mM for 1 recep-
tor) [19], with subnanomolar 1 receptor afﬁnity (Ki =0.42nM)
and 86-fold higher selectivity toward the 2 subtype. In addi-
tion, selectivity against other CNS receptors (e.g., serotonergic and
dopaminergic) was shown for this compound [21]. Treatment of
zebraﬁsh larvae with the 1 speciﬁc agonist PB190, as well as the
reference compoundDTG, signiﬁcantly reducedmicroglial reaction
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Fig. 1. 1 Receptor is important for microglial reaction toward injury.
(A) Percentage of microglia reacting to injury in DMSO compared to DTG and PB190 treated zebraﬁsh larvae. (B) Speed of microglia branch extension and retraction in DMSO,
DTG and PB190 treated embryos. (C) Time course of microglia (pU1::Gal4-UAS::TagRFP) reaction toward injuries in DMSO treated embryos. (C1) before, (C2) 10min after
and (C3) 90min after cut. (D) Time course of microglia (pU1::Gal4-UAS::TagRFP) reaction toward injuries in PB190 treated embryos. (D1) before, (D2) 10min after and (D3)
90min after cut. (E) Dorsal views of a 3,5 dpf larval brain showing the time course of a Ca2+ wave (beta-actin::GCaMP3.1) forming upon central brain injury in PB190 treated
zebraﬁsh larvae. (E1) before, (E2) 2 s after and (E3) 12 s after cut. Scalebar for all images 20m. Images (C) and (D) were obtained using an Andor Spinning Disk Confocal
with a 40x/NA1.15 objective. Images (E) were produced using an Olympus FV 1000 with a 40x/NA1.15 objective. Statistical analysis was performed using a Kruskal-Wallis
test with a Dunn’s multiple comparison test.
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Fig. 2. Treatment with 1 agonist does not lead to a clearance phenotype.
(A) Acridine orange staining of 3,5dpf zebraﬁsh larvae treated with DMSO. (B) Acridine orange staining of 3,5dpf zebraﬁsh larvae treated with DTG. (C) Acridine orange
staining of 3,5dpf zebraﬁsh larvae treated with PB190. (D) Quantiﬁcation of uncollected acridine orange positive cells in a 3,5dpf larvae treated with DMSO, DTG or PB190.
Scalebar for all images 20m. All images were obtained using an Andor Spinning Disk Confocal with a 20x/NA0.7 objective. Statistical analysis was performed using a
Kruskal–Wallis test with a Dunn’s multiple comparison test.
toward damage (Fig. 1A, Fig. 1D1–D3). While in DMSO controls,
microglia responded to a nearby injury by redirecting their branch-
ing toward damage, in treated embryos they failed to do so even
90min after damage (Fig. 1A compare Fig. 1C1–C3 with D1–D3
and compare movie 1 with movie 2). This drug treatment did not
inﬂuence Ca2+ signaling which was shown to be necessary and suf-
ﬁcient for microglial reactions (Fig. 1E; [20]. Interestingly, even
though treatment with 1 agonists blocks the reaction of microglia
toward neuronal injuries, the cellular baseline activity of these
cells, deﬁned in terms of branch extension and retraction speed,
did not change signiﬁcantly in treated larvae compared to controls
(Fig. 1B and movie 1 and movie 2), indicating that these chemicals
do not affect general microglial motility. During brain develop-
ment microglia collect apoptotic neurons, a function which is of
great importance for brain development. Labeling of apoptotic cells
in vivobyusingacridineorangeallowedassessingmicroglial behav-
ior in response to neuronal cell death. In embryos treatedwith both
DTG and PB190 microglia appeared more roundish (Fig. 1D). How-
ever, they collected apoptotic neurons at a normal rate as shown
by equal numbers of uncollected apoptotic cells in drug treated and
DMSOcontrol embryos (Fig. 2A–D). Thus,weconclude thatDTGand
PB190 are speciﬁcally blocking microglial responses to neuronal
injuries without affecting other important aspects of microglial
biology, such as branching dynamics and engulfment of apoptotic
neurons.
3.2. 1 Receptor is involved in “switching-off” microglia allowing
for these cells to leave the site of damage
Next,wewanted to establish if thephenotype thatweobserve in
the living zebraﬁsh brain using DTG and PB190 is indeed due to 1
receptors activation in vivo. For this, we combined drug treatment
with reverse genetics and knocked-down the 1 using a mor-
pholino that blocks translation as conﬁrmed by using an antibody
against the 1 receptor (Fig. 3A). The knock-down of the 1 recep-
tor completely abolished the effect of PB190, and indeed in treated
morphant brainsmicroglia can respond to an injury bymigrating to
the site of damage (Fig. 3C). To investigate the functional require-
ment of 1 in microglia, we examined the knock-down phenotype
upon brain injuries. We found that in 1 morphant embryos sub-
jected to an injury microglia respond at a normal rate (Fig. 3C).
However, while in control embryos the ﬁrstmicroglia leave the site
of damage after around 249min, in morphant embryos microglia
remain signiﬁcantly longer with the ﬁrst cells leaving after around
420min (Fig. 3B). Interestingly, in PB190 treated embryos, a frac-
tion of the microglia (24%) still responds to injury. These microglia
that have reached the site of damage in PB190 treated embryos stay
only shortly and leave after around 74min (Fig. 3B). All together
these ﬁndings point to a clear role for the 1 receptor inmodulating
microglial responses to damage. In particular, we ﬁnd that the role
of this receptor is to allow microglia to move away from damage.
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Fig. 3. The 1 receptor allows for microglia to leave the site of damage.
(A) 1-Mo mediated knock-down on protein level. (B) Quantiﬁcation of time until ﬁrst microglia cell leaves the site of injury in DMSO compared to PB190 treated embryos
with larvae lacking their 1 receptor. (C) Percentage of microglia reacting to an injury in DMSO and PB190 treated compared to larvae lacking their 1 receptor and PB190
treated 1 knock-down embryos. Statistical analysis was performed using a Kruskal–Wallis test with a Dunn’s multiple comparison test.
Thus, modulation of 1 receptor activity can be used to reduce the
devastating impact of neuroinﬂammation andmicroglial responses
in the context of many neurodegenerative diseases.
4. Discussion
In this study,we show that the role of 1 in vivo is to “switch-off”
microglia reaction toward injuries allowing for these cells to leave
the site of damage. In 1 receptor knock-down microglia remain
much longer at the site of damage, while, in brain treated with
1 agonist, these cells move away quickly. Moreover, we show
that the action of 1 on microglia is really speciﬁc to damage
responses. Indeed, in embryos treated with 1 agonists microglia
do not respond to injury but they maintain other activities such
as branching and engulfment of apoptotic neurons that are gen-
erated during development. To the best of our knowledge, this is
the ﬁrst in vivo real-time imaging study of 1-modulatedmicroglial
responses.
Given the importance of microglia both in development and
in the context of many neurological disorders, many studies
have focused on these cells and their response to brain damage.
However, to better understand microglia and their molecular mod-
ulators, such as the 1 receptor, it is crucial to preserve the normal
morphology and dynamics of this cellular network and to work in
the context of the intact brain. The work described here takes full
advantage of the optical transparency of the small zebraﬁsh brain.
The embryo is alive under the microscope and can be manipulated
both genetically and pharmaceutically by simply adding chemi-
cal compounds to the medium. In this way, the role of molecules
involved in modulating microglial functions and behaviors can be
testeddirectly in vivo. In thisway,we found that treatmentwith the
high-afﬁnity and highly selective 1 receptor agonist PB190 or ref-
erence compound DTG, drastically reduces migration of microglial
cells toward damage (Fig. 1A and Fig. 1D1–D3). This effect is very
speciﬁc and restricted to injury responses, as these two compounds
do not affect other aspects of the microglial behavior, such as scan-
ning the brain and collecting apoptotic neurons. Most importantly,
wealso showthat applicationof these chemicals doesnot affect sig-
naling transmission within the brain. Indeed, we have found that
Ca2+ signaling, necessary for ATP release and microglial reactions
to brain injuries [20], is not affected in 1 receptor agonist treated
brains.
Finally, in this study, we identify the role of 1 receptor in vivo,
which is to switch off microglia allowing for these cells to leave
the site of damage. Indeed, morphant microglia move to sites of
injury as expected but remain there signiﬁcantly longer. Interest-
ingly, it has been shown that ATP attractsmicroglia toward damage
via activation of P2Y12 on microglia [9]. It has also been shown
that the -receptor agonist afobazole inhibits microglial response
mediated by P2Y and P2X purinergic receptors [4]. Therefore,
activation of -receptor at the site of damage might reduce
microglial response to ATP allowing for these cells to move away.
Thus, one key ﬁnding of this study is the fact that after trau-
matic injury, activation of -receptor using speciﬁc agonists, might
resolve inﬂammation and prevent chronic microglial responses.
The demonstration that microglial responses can be modulated
pharmacologically by 1 receptor activation could unlock new
approaches for future therapeutic applications.
All in all, the present study provides strong support to the cru-
cial role that 1 receptors play in the modulation of microglia, and
strongly encourages further investigation on 1 receptors for the
prevention of chronic neuroinﬂammation, shedding light on novel
opportunities to reduce the devastating impact that microglia have
in many neurodegenerative diseases.
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